As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders have been left debating how they can navigate this shifting landscape—or even whether biotechs should abandon China altogether. The latest complication comes from Rep. John Moolenaar (R-MI), chair of the U.S. House Select Committee on China, who fired off letters to four Big Pharmas last week. The allegations in the letters ranged from human rights violations in a specific region of the country to concerns about inadvertently aiding China’s military. The letters are the latest salvo in the political debate about China’s growing prominence as a source of new drugs for U.S. companies. Other strategies to temper this growth have included an ongoing discussion about limiting investment in Chinese biotechs via an amendment to the COINS Act.

Full report : As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense.’